Nextera logo
  • About us
    • Management
    • Board of Directors
  • Technology
  • News & Events
  • Careers
  • Contact

Nextera joins the BIO International Convention

May 18, 2020 | Meet us

CEO Geir Åge Løset and CBO Ole Henrik Brekke will attend the BIO International Convention June 8th – 12th. Book us for a digital meeting and we will present our unique NextCore Immunology platform. Learn how this technology can leverage the target and drug discovery in complex immunological diseases.   https://www.bio.org/events/bio-digital

← Previous Next →

Recent

  • Nextera’s NextCore technology applied to develop a unique peptide activator of the tissue injury Factor-VII activating protease (FSAP) in human plasma
  • Nextera’s unique NextCore display technology combined with state-of-the-art computational guidance efficiently generates low picomolar affinity TCR-Like antibodies
  • Nextera AS announces strategic collaboration with Zelluna Immunotherapy AS on development of optimized TCRs for redirected cancer immunotherapy
  • NextCore-generated state-of-the-art TCR-Like antibodies in celiac disease published in Science Immunology.
  • Nextera appoints Dr. Bent Jakobsen to the Board of Directors

Sort by

  • Meet us
  • News
  • Publications

Nextera AS

Oslo Innovation Centre
Gaustadalléen 21
, 0349 Oslo, Norway

  • Follow

Cookie Policy

Copyright 2020 Nextera AS
Design by Færd

Contact

Phone: +47 22 95 81 94
Mail: info@nextera.no

Navigation

About us
Management
Board of Directors
Technology
News & Events
Contact

Recent news

Nextera’s NextCore technology applied to develop a unique peptide activator of the tissue injury Factor-VII activating protease (FSAP) in human plasma

Oct 20, 2022

Factor-VII activating protease (FSAP) is a ubiquitously circulating zymogen plasma serine protease, which is rapidly activated upon tissue injury. FSAPs role in sepsis, trauma, stroke, and acute respiratory distress syndrome suggests that pro-FSAP activation is...

Nextera’s unique NextCore display technology combined with state-of-the-art computational guidance efficiently generates low picomolar affinity TCR-Like antibodies

Aug 26, 2022

The antibody engineering field is steadily evolving harnessing improvements in discovery engines and computational methods. Together with collaborators at OUS/UiO (Norway) and John Hopkins (US), we here describe a very powerful combination of the highly efficient...

Copyright 2020 Nextera AS
Design by Færd

Copyright 2020 Nextera AS
Design by Færd